CDA Type I | Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC

CDA Type I research study

What is the primary objective of this study?

Who is eligible to participate?

Inclusion Criteria: - patients with CDAI - over 30 kg - can swallow tablets - ferritin levels higher than the normal range but still don't require treatment. Exclusion Criteria: - N.A

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

CDA Type I

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.


Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

LOSECLOSEC will be given 20 mg X 1/day for 6 months and then for the next 6 months the same group will be the "control" group of herself.

Study Status

Unknown status

Start Date: April 2013

Completed Date: December 2013

Phase: Phase 4

Type: Interventional


Primary Outcome: evaluate number of adverse effects per patient treated with LOSEC + levels of iron, ferritin,complete blood count and chemistry panel.

Secondary Outcome:

Study sponsors, principal investigator, and references

Principal Investigator:

Lead Sponsor: Soroka University Medical Center


More information:

Discuss Prilosec